About BostonGene
BostonGene is a Healthcare company based in Waltham (United States) founded in 2015 by Andrew Feinberg. Developer of cloud-based information and analytics platform to treat cancer. BostonGene has raised $200 million across 2 funding rounds from investors including NEC, Impact Investment Exchange and Japan Industrial Partners. The company has 364 employees. BostonGene was last valued at $1 billion in January 2026. Its chief executive, as recorded, is Andrew Feinberg. Its website bostongene.com draws about 13 thousand monthly visits. BostonGene offers products and services including BostonGene Tumor Portraitâ„¢ Test, Liquid Biopsy, and Immunohistochemistry (IHC) Test. Its focus areas include Life Sciences, Genomics, Genome Informatics and Integrative Bioinformatics Platforms. Its legal entity is BostonGene Corporation. Its competitors include Helix, Syapse and Benchling; 3 of its 3 listed competitors have raised funding.
Company details
BostonGene was founded in 2015 and is headquartered in Waltham, United States. Operations focus on the healthcare and biotechnology sectors, where a cloud-based platform integrates AI, algorithms, and modern technologies. Molecular profiles of patient tumors are analyzed, combining tumor microenvironment, genetic data, and clinical information. Results are delivered directly to medical professionals through the MF Portrait platform to support oncology decisions.
- Headquarters Waltham, United States
- Employees 364
- Founders Andrew Feinberg
- Stage Unicorn
- SectorsHealthcare
- Phone•••• ••••
- Website bostongene.com
- Social LinkedIn X Facebook YouTube
- Legal Name Bostongene Corporation
- Total Equity Funding$200M (USD)
in 2 rounds
- Latest Funding Round$150M (USD), Series B
Apr 2022
- InvestorsNEC
& 2 more
- Employee Count364
Products & Services of BostonGene
BostonGene offers a comprehensive portfolio of products and services, including BostonGene Tumor Portrait™ Test, Liquid Biopsy, and Immunohistochemistry (IHC) Test.
Offers comprehensive molecular profiling for cancer patients
Provides non-invasive testing for tumor analysis
Detects actionable biomarkers in cancer samples
Apps and channels of BostonGene
its YouTube channel BostonGene has 90 subscribers and 6 videos.
Videos from BostonGene
The most watched videos on BostonGene's YouTube channel, BostonGene (90 subscribers). Click a video to play it here.
More on BostonGene.
Funding Insights of BostonGene
BostonGene has successfully raised a total of $200M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $150 million completed in April 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $200M
- Total Rounds 2
- Last Round Series B — $150M
- First Round $50M
(Apr 2019)
- Investors Count 3
All 2 funding rounds of BostonGene with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Valuation | Stage |
|---|---|---|
| Apr 2022 | $1B | •••••••• |
Last known valuation $1B (Jan 2026). 3 investors in total: 3 institutional.
Investors in BostonGene
BostonGene has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include NEC, Impact Investment Exchange and Japan Industrial Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity investments are directed toward women empowerment initiatives. | iixglobal.com | Singapore, Singapore | ||
Japan Industrial Partners is engaged in industrial revitalization and growth. | jipinc.com | Japan | ||
Cloud-based IT and networking solutions are provided globally. | 1899 | nec.com | Minato City, Japan |
Investor details for BostonGene
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of BostonGene
110 people are tracked at BostonGene (36 in leadership, 74 in team); the tracked headcount is 364.
| Name | Role | Group |
|---|---|---|
Andrew Feinberg | Co-Founder & CEO | Leadership |
David A. | VP Of Strategy | Leadership |
Zara Ohanyan | HR Business Partner | Leadership |
Joe Lennerz | Chief Scientific Officer | Leadership |
Connor Wallace | Director, Biopharma Business Development | Leadership |
Ann Ogloblina | Director of Product Management | Leadership |
Stephen J. Quinlan | Vice President, Legal | Leadership |
Vladimir Saturchenko | Technical Director | Leadership |
Alexander Bagaev | Chief Product Officer | Leadership |
Nathan Fowler, MD | Chief Medical Officer | Leadership |
Maria Dobychina | Head of Human Resources Sector | Leadership |
Anastasia Terenteva | Head Of Project Management Office | Leadership |
Katerina Postovalova | Director Program Management | Leadership |
Erin O'Reilly | Senior Director, Marketing | Leadership |
Michael Goldberg | VP R&d | Leadership |
Mehak Nogueira, RAHP | Senior Director Quality Assurance | Leadership |
Melissa Rae Olsson | VP of Finance | Leadership |
Ferran Prat Escude | Chief Commercial Officer (cco) | Leadership |
Ricky Boyle | VP AI Solutions | Leadership |
Rheanna Carter, MBA | Director Of Business Development | Leadership |
90 more people are available in the full profile.
Complete people profiles for BostonGene
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of BostonGene
4 dated milestones of BostonGene across 7 years, from founding to its latest funding, stage changes and deals.
- Founded BostonGene is founded.
- Funding First funding round of $50.0M.
- Funding Latest funding round, Series B, of $150.0M.
- Milestone Reaches Unicorn status.
Competitors of BostonGene
BostonGene has 3 listed competitors in our database, 3 of them funded. They include Helix, Syapse and Benchling.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| helix.com | 2015 | San Francisco, United States | $435M | Genomic database for clinical research is provided. | ||
| syapse.com | 2008 | San Francisco, United States | $221.1M | 209 | Developer of precision medicine for the treatment of cancer | |
| benchling.com | 2012 | San Francisco, United States | $411.9M | 640 | Cloud-based bioinformatics platform is offered for biotech research. |
Detailed competitors of BostonGene
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of BostonGene
The website of BostonGene (bostongene.com) receives about 13.4K visits a month.
- Monthly visits13.4K
▲ 39.9% vs previous month
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as BostonGene (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Bostongene
Complete news archive for BostonGene
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about BostonGene
BostonGene was founded in 2015 and raised its 1st funding round 4 years after it was founded.
BostonGene is headquartered in Waltham, United States. It is registered at Waltham, Massachusetts, United States.
Andrew Feinberg is the CEO of BostonGene, as recorded in our data. They have also founded this company.
BostonGene is a funded company, having raised a total of $200M across 2 funding rounds to date. The company's 1st funding round was a Series A of $50M, raised on Apr 2019.
BostonGene has 364 employees.
BostonGene was founded in 2015 and is headquartered in Waltham, United States. Operations focus on the healthcare and biotechnology sectors, where a cloud-based platform integrates AI, algorithms, and modern technologies. Molecular profiles of patient tumors are analyzed, combining tumor microenvironment, genetic data, and clinical information. Results are delivered directly to medical professionals through the MF Portrait platform to support oncology decisions.
BostonGene offers BostonGene Tumor Portraitâ„¢ Test, Liquid Biopsy, and Immunohistochemistry (IHC) Test.
BostonGene has 3 investors. Key investors include NEC, Impact Investment Exchange, and Japan Industrial Partners.
The valuation of BostonGene is $1B as of Jan 2026.
BostonGene operates through Bostongene Corporation.